Respiratory Distress Syndrome, Adult Clinical Trial
— SOLVE ARDSOfficial title:
Strategies for Optimal Lung Ventilation in ECMO for ARDS: The SOLVE ARDS Study
Due to lack of studies on mechanical ventilation strategies in patients with severe Acute
Respiratory Distress Syndrome (ARDS) supported with Veno-Venous Extra-Corporeal Membrane
Oxygenation (VV ECMO), ventilator settings in this patient population are set arbitrarily.
In this two-phases prospective, interventional, pilot study we hope to gain physiologically
relevant data on two aspects of mechanical ventilation in patients with severe ARDS
supported with VV ECMO: (1) the use of tidal ventilation and (2) the level of Positive
End-Expiratory Pressure (PEEP).
1. PHASE 1: impact of tidal ventilation on VILI (10 patients) We hypothesized that a CPAP
strategy that minimizes end-tidal pulmonary stress and strain mitigates VILI compared
to the current mechanical ventilation practice that employs tidal ventilation in
patients with severe ARDS on ECMO.
In this first phase we will test whether administering a distending inspiratory
pressure to produce tidal ventilation is superior to a strategy where only continuous
positive airway pressure (CPAP) is applied for ventilation induced lung injury (VILI)
mitigation, as assessed by its impact on biotrauma (serum cytokines) and physiologic
measurements.
2. PHASE 2: impact of PEEP on VILI (10 patients) We also hypothesized that adjusting PEEP
to maximize respiratory system compliance reduces VILI in patients with severe ARDS on
ECMO.
In the second phase we will therefore gain more insight as to whether a strategy that
utilizes a PEEP level that correspond to best compliance is beneficial over Zero
End-Expiratory Pressure (ZEEP). We will test the impact of both strategies on biotrauma
(serum cytokines), physiologic parameters, and right ventricular function (transesophageal
echocardiographic assessment).
Because ARDS patients supported with VV ECMO can be hemodynamically unstable, the use of
imaging techniques that require transport, such as computed tomography, is limited.
Therefore, bedside imaging techniques, such as pleural and lung ultrasound (PLUS) and
focused bedside cardiac ultrasonography, are important tools for clinicians who care for
these patients. This study will allow us to learn whether these techniques are feasible and
valid in this patient population.
Furthermore, the knowledge gained from this study will allow us to assess the rationale and
feasibility of performing a similar larger, randomized study in the future.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 16 Years and older |
Eligibility |
Inclusion Criteria: - Severe ARDS (Berlin Definition) - VV ECMO < 72 hours - Endotracheal intubation or tracheostomy Exclusion Criteria: - Thoracic surgery/lung transplantation during the current hospitalization - Contraindications to a RM (MAP < 60 mmHg despite administration of fluids and vasopressors; Active air leak through a thoracostomy tube; Pneumothorax, or subcutaneous or mediastinal emphysema, (if chest tube has not been inserted)) - Contraindications to TEE - Age < 16 years |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Canada | Medical Surgical ICU - Toronto General Hospital | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
University of Toronto | The Physicians' Services Incorporated Foundation, University Health Network, Toronto |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ventilator-Induced Lung Injury (VILI) in patients with ARDS on ECMO ventilated with different strategies (tidal ventilation, CPAP, ZEEP), as measured by Serum Cytokines | 1 hour after initiation of each experimental ventilation strategy | Yes | |
Secondary | Impact of a CPAP strategy (PEEP set at best compliance and at ZEEP) in patients with severe ARDS on ECMO, as measured by transesophageal echocardiography (TEE) | Quantification of RV function: RVEDA/LVEDA LV end-diastolic/systolic eccentricity indexes: 2D RVFAC TAPSE Tissue Doppler-derived tricuspid lateral annular systolic velocity (S') RIMP 3D EF < 44% Myocardial Acceleration During Isovolumic Contraction Regional RV Strain |
30 minutes after initiation of experimental CPAP/ZEEP strategy | No |
Secondary | Feasibility and validity of focused cardiac ultrasound, as compared to TEE as gold standard, in the assessment of RV function in patients with ARDS on ECMO | Quantification of RV function: RVEDA/LVEDA TAPSE RV Annular Velocity (S') LV end-diastolic and end-systolic eccentricity indexes |
30 minutes after initiation of experimental CPAP/ZEEP strategy | No |
Secondary | Feasibility of lung ultrasound in patients with severe ARDS on ECMO | Lung Ultrasound Score | 30 minutes after initiation of experimental CPAP/ZEEP strategy | No |
Secondary | Feasibility (patient recruitment, protocol adherence, physiologic tolerability) | This outcome will be assessed by: the ability to enrol the proposed patient sample within the timeframe of the study (24 months) >90% adherence to the experimental protocol on enrolled patients >80% completion of the entire experimental protocol on enrolled patients |
At overall study completion (i.e., 24 months from study start or after enrolment of last patient) | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03712215 -
STUDY OF ELECTRICAL STIMULATION IN PULMONARY FUNCTION IN INTENSIVE CARE UNIT
|
N/A | |
Completed |
NCT04582201 -
Evaluate the Safety of agenT-797 in Participants With Moderate to Severe Difficulty Breathing Secondary to SARS-CoV-2
|
Phase 1/Phase 2 | |
Completed |
NCT01167621 -
Changes in Refractory Acute Respiratory Distress Syndrome (ARDS) Patients Under High Frequency Oscillation-ventilation
|
N/A | |
Terminated |
NCT00233207 -
IC14 Antibodies to Treat Individuals With Acute Lung Injury
|
Phase 2 | |
Completed |
NCT00029328 -
Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT00004494 -
Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis
|
Phase 1 | |
Completed |
NCT00000579 -
Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)
|
Phase 3 | |
Recruiting |
NCT03236272 -
Establishment of a Biomarkers-based Early Warning System of Acute Respiratory Distress Syndrome (ARDS)
|
||
Withdrawn |
NCT04508933 -
Comparison of Extra Vascular Lung Water Index in Covid-19 ARDS and "Typical"ARDS Patients
|
||
Completed |
NCT02273687 -
Time-motion-mode Ultrasound Diaphragm Measures in Patients With Acute Respiratory Distress in Emergency Department
|
N/A | |
Recruiting |
NCT03424798 -
Measuring Heart and Lung Function in Critical Care
|
N/A | |
Recruiting |
NCT01992237 -
Measuring Energy Expenditure in ECMO (Extracorporeal Membrane Oxygenation) Patients
|
N/A | |
Completed |
NCT00719446 -
Evaluating Health Outcomes and QOL After ALI Among Participants of the ALTA, OMEGA, EDEN, and SAILS ARDS Network Trials
|
N/A | |
Completed |
NCT00236262 -
Effect of Positive Expiratory Pressure on Right Ventricular Function in Patients With Respiratory Distress Syndrome
|
N/A | |
Completed |
NCT00300248 -
Long-Term Results in Mechanically Ventilated Individuals With Acute Lung Injury/Acute Respiratory Distress Syndrome
|
N/A | |
Completed |
NCT00157144 -
Australia and New Zealand Adult Extracorporeal Membrane Oxygenation (ECMO) Audit 2005
|
N/A | |
Completed |
NCT00141726 -
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
|
Phase 2 | |
Recruiting |
NCT00465374 -
A Validation/Interventional Study on Stress Index in Predicting Mechanical Stress in ARDS Patients
|
Phase 3 | |
Completed |
NCT00094406 -
Carbon Monoxide to Prevent Lung Inflammation
|
Phase 1 | |
Recruiting |
NCT03709199 -
Long Term Follow up of Children Enrolled in the REDvent Study
|